扶正清鼻方辅助放疗治疗鼻咽癌40例

发布时间：2018-04-23 12:10

  本文选题：鼻咽癌 + 扶正清鼻方　； 参考：《中国实验方剂学杂志》2014年13期

【摘要】：目的:探讨扶正清鼻方辅助放疗治疗鼻咽癌(NPC)放射性口腔黏膜损伤及对血浆脱氧核糖核酸(EBV-DNA),血清EB病毒衣壳抗原抗体(VCA-IgA)和早期抗原抗体(EA-IgA)的影响。方法:将80例NPC患者随机按入诊前后顺序分为对照组和观察组各40例。对照组进行放疗+对症支持治疗。观察组在对照组治疗的基础上加服扶正清鼻方,1剂/d。两组疗程均为12周。观察放射性口腔黏膜损伤出现时间及程度,于第3,7周进行生活质量评分;采用聚合酶链式反应法(PCR)检测血浆EBV-DNA水平;采用酶联免疫吸附剂测定(ELISA)检测血清VCA-IgA和EA-IgA水平。结果:治疗后第3周,观察组放射性口腔黏膜损伤Ⅲ级反应发生率为40%,对照组为57.5%,差异无统计学意义;观察组Ⅳ级反应发生率为2.5%,对照组为17.5%,差异有统计学意义(P0.05);治疗后第7周,观察组Ⅲ级反应发生率为55%,对照组为70%;治疗组Ⅳ级反应发生率为7.5%,对照组为25%,差异有统计学意义(P0.05);对照组出现放射性口腔黏膜反应时间为(18.5±2.8)d,观察组为(15.5±2.7)d,观察组晚于对照组(P0.01);治疗后观察组血浆EBV-DNA水平低于对照组(P0.01);治疗后观察组血清VCA-IgA和EA-IgA水平低于对照组(P0.01)。结论:扶正清鼻方能减轻鼻咽癌放射性口腔黏膜损伤,并能抑制咽癌血清EB病毒,降低血清病毒抗体水平,这可能对NPC复发或转移抑制作用。
[Abstract]:Objective: to investigate the effects of Fuzheng Qingbifang (FQB) in the treatment of oral mucosal injury of nasopharyngeal carcinoma (NPC) and its effects on plasma DNA EBV-DNA, serum EB virus capsid antigen antibody (VCA-IgA) and early antigen antibody (EA-IgA). Methods: 80 patients with NPC were randomly divided into control group (n = 40) and observation group (n = 40). The control group was treated with radiotherapy and symptomatic support therapy. Observation group on the basis of the treatment of the control group plus Fuzheng Qingbei prescription 1 / d. The course of treatment was 12 weeks in both groups. To observe the time and degree of radiation oral mucosal injury, the quality of life (QOL) score was evaluated at the 3rd week, the plasma EBV-DNA level was detected by polymerase chain reaction (PCR), and the serum VCA-IgA and EA-IgA levels were detected by enzyme linked immunosorbent assay (Elisa). Results: at the 3rd week after treatment, the incidence of grade 鈪，

本文编号：1791918